Compare Suven Life Sciences with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE SCIENCES vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE SCIENCES AJANTA PHARMA SUVEN LIFE SCIENCES/
AJANTA PHARMA
 
P/E (TTM) x -79.8 24.7 - View Chart
P/BV x 1.3 6.9 18.3% View Chart
Dividend Yield % 1.8 0.5 356.9%  

Financials

 SUVEN LIFE SCIENCES   AJANTA PHARMA
EQUITY SHARE DATA
    SUVEN LIFE SCIENCES
Mar-19
AJANTA PHARMA
Mar-19
SUVEN LIFE SCIENCES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3381,422 23.7%   
Low Rs169898 18.9%   
Sales per share (Unadj.) Rs52.1233.5 22.3%  
Earnings per share (Unadj.) Rs6.844.0 15.5%  
Cash flow per share (Unadj.) Rs8.652.2 16.4%  
Dividends per share (Unadj.) Rs1.509.00 16.7%  
Dividend yield (eoy) %0.60.8 76.2%  
Book value per share (Unadj.) Rs65.3255.1 25.6%  
Shares outstanding (eoy) m127.2888.02 144.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.95.0 97.9%   
Avg P/E ratio x37.126.4 140.7%  
P/CF ratio (eoy) x29.622.2 133.0%  
Price / Book Value ratio x3.94.5 85.4%  
Dividend payout %22.020.5 107.3%   
Avg Mkt Cap Rs m32,272102,081 31.6%   
No. of employees `0001.16.8 15.9%   
Total wages/salary Rs m6614,307 15.4%   
Avg. sales/employee Rs Th6,132.23,022.6 202.9%   
Avg. wages/employee Rs Th611.1633.4 96.5%   
Avg. net profit/employee Rs Th803.5569.1 141.2%   
INCOME DATA
Net Sales Rs m6,63520,554 32.3%  
Other income Rs m242211 114.9%   
Total revenues Rs m6,87720,765 33.1%   
Gross profit Rs m1,6045,664 28.3%  
Depreciation Rs m221721 30.7%   
Interest Rs m3812 325.0%   
Profit before tax Rs m1,5875,143 30.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7181,273 56.4%   
Profit after tax Rs m8693,870 22.5%  
Gross profit margin %24.227.6 87.7%  
Effective tax rate %45.224.8 182.7%   
Net profit margin %13.118.8 69.6%  
BALANCE SHEET DATA
Current assets Rs m6,23211,812 52.8%   
Current liabilities Rs m1,4903,776 39.5%   
Net working cap to sales %71.539.1 182.8%  
Current ratio x4.23.1 133.7%  
Inventory Days Days8677 111.7%  
Debtors Days Days8382 101.2%  
Net fixed assets Rs m4,04314,398 28.1%   
Share capital Rs m127175 72.6%   
"Free" reserves Rs m8,18322,277 36.7%   
Net worth Rs m8,31022,452 37.0%   
Long term debt Rs m187 269.7%   
Total assets Rs m10,38926,962 38.5%  
Interest coverage x43.1444.3 9.7%   
Debt to equity ratio x00 728.7%  
Sales to assets ratio x0.60.8 83.8%   
Return on assets %8.714.4 60.7%  
Return on equity %10.517.2 60.7%  
Return on capital %19.523.0 85.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62210,682 52.6%   
Fx outflow Rs m1,7992,102 85.6%   
Net fx Rs m3,8228,580 44.6%   
CASH FLOW
From Operations Rs m3563,748 9.5%  
From Investments Rs m-279-2,228 12.5%  
From Financial Activity Rs m-225-1,475 15.3%  
Net Cashflow Rs m-14845 -327.9%  

Share Holding

Indian Promoters % 63.4 73.8 85.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 1.6 -  
FIIs % 0.0 7.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 17.0 214.7%  
Shareholders   37,287 20,968 177.8%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE SCIENCES With:   TORRENT PHARMA  NATCO PHARMA  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare SUVEN LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Wipro's Biggest Acquisition, Vodafone Idea Fundraising Plan, and Buzzing Stocks Today(Pre-Open)

Indian share markets witnessed huge selling during closing hours on Friday and ended lower.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 60.8% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SCIENCES SHARE PRICE


Mar 5, 2021 (Close)

TRACK SUVEN LIFE SCIENCES

  • Track your investment in SUVEN LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFE SCIENCES

SUVEN LIFE SCIENCES - DIVIS LABORATORIES COMPARISON

COMPARE SUVEN LIFE SCIENCES WITH

MARKET STATS